Find Oncology Drugs in Phase I Clinical Development in CHINA

Lead Product(s): BGB-3245

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

The Phase 1 clinical trial is a first-in-human study to investigate the safety, pharmacokinetics and antitumor activity of BGB-3245 in adult patients with solid tumors.

Lead Product(s): Niraparib

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

Details:

Phase 1b study of Niraparib in combination with MGD013 in advanced or metastatic gastric cancer in China.

Lead Product(s): SCB-313

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

The Phase I, open-label, dose escalation trial in China is designed to assess the safety, tolerability, pharmacokinetics and efficacy of intrapleural administered SCB-313 for the treatment of MPE.

Lead Product(s): Adg106

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: General Atlantic

Deal Size: $69.0 million Upfront Cash: Undisclosed

Deal Type: Series D Financing January 08, 2020

Details:

Proceeds will support advancement of lead immunotherapy clinical programs ADG106 and extend the frontiers of novel technology.